666 related articles for article (PubMed ID: 29437574)
1. CSL112 (Apolipoprotein A-I [Human]) Enhances Cholesterol Efflux Similarly in Healthy Individuals and Stable Atherosclerotic Disease Patients.
Gille A; D'Andrea D; Tortorici MA; Hartel G; Wright SD
Arterioscler Thromb Vasc Biol; 2018 Apr; 38(4):953-963. PubMed ID: 29437574
[TBL] [Abstract][Full Text] [Related]
2. Novel formulation of a reconstituted high-density lipoprotein (CSL112) dramatically enhances ABCA1-dependent cholesterol efflux.
Diditchenko S; Gille A; Pragst I; Stadler D; Waelchli M; Hamilton R; Leis A; Wright SD
Arterioscler Thromb Vasc Biol; 2013 Sep; 33(9):2202-11. PubMed ID: 23868939
[TBL] [Abstract][Full Text] [Related]
3. CSL112 enhances biomarkers of reverse cholesterol transport after single and multiple infusions in healthy subjects.
Gille A; Easton R; D'Andrea D; Wright SD; Shear CL
Arterioscler Thromb Vasc Biol; 2014 Sep; 34(9):2106-14. PubMed ID: 24969776
[TBL] [Abstract][Full Text] [Related]
4. Infusion of Reconstituted High-Density Lipoprotein, CSL112, in Patients With Atherosclerosis: Safety and Pharmacokinetic Results From a Phase 2a Randomized Clinical Trial.
Tricoci P; D'Andrea DM; Gurbel PA; Yao Z; Cuchel M; Winston B; Schott R; Weiss R; Blazing MA; Cannon L; Bailey A; Angiolillo DJ; Gille A; Shear CL; Wright SD; Alexander JH
J Am Heart Assoc; 2015 Aug; 4(8):e002171. PubMed ID: 26307570
[TBL] [Abstract][Full Text] [Related]
5. High-Density Lipoprotein Subfractions and Cholesterol Efflux Capacities After Infusion of MDCO-216 (Apolipoprotein A-IMilano/Palmitoyl-Oleoyl-Phosphatidylcholine) in Healthy Volunteers and Stable Coronary Artery Disease Patients.
Kempen HJ; Asztalos BF; Moerland M; Jeyarajah E; Otvos J; Kallend DG; Bellibas SE; Wijngaard PL
Arterioscler Thromb Vasc Biol; 2016 Apr; 36(4):736-42. PubMed ID: 26916733
[TBL] [Abstract][Full Text] [Related]
6. CSL112 (Apolipoprotein A-I [Human]) Strongly Enhances Plasma Apoa-I and Cholesterol Efflux Capacity in Post-Acute Myocardial Infarction Patients: A PK/PD Substudy of the AEGIS-I Trial.
Gibson CM; Kazmi SHA; Korjian S; Chi G; Phillips AT; Montazerin SM; Duffy D; Zheng B; Heise M; Liss C; Deckelbaum LI; Wright SD; Gille A
J Cardiovasc Pharmacol Ther; 2022; 27():10742484221121507. PubMed ID: 36282079
[TBL] [Abstract][Full Text] [Related]
7. Moderate Renal Impairment Does Not Impact the Ability of CSL112 (Apolipoprotein A-I [Human]) to Enhance Cholesterol Efflux Capacity.
Gille A; Duffy D; Tortorici MA; Wright SD; Deckelbaum LI; D'Andrea DM
J Clin Pharmacol; 2019 Mar; 59(3):427-436. PubMed ID: 30452776
[TBL] [Abstract][Full Text] [Related]
8. Safety and Tolerability of CSL112, a Reconstituted, Infusible, Plasma-Derived Apolipoprotein A-I, After Acute Myocardial Infarction: The AEGIS-I Trial (ApoA-I Event Reducing in Ischemic Syndromes I).
Michael Gibson C; Korjian S; Tricoci P; Daaboul Y; Yee M; Jain P; Alexander JH; Steg PG; Lincoff AM; Kastelein JJ; Mehran R; D'Andrea DM; Deckelbaum LI; Merkely B; Zarebinski M; Ophuis TO; Harrington RA
Circulation; 2016 Dec; 134(24):1918-1930. PubMed ID: 27881559
[TBL] [Abstract][Full Text] [Related]
9. ApoA-I Infusion Therapies Following Acute Coronary Syndrome: Past, Present, and Future.
Kalayci A; Gibson CM; Ridker PM; Wright SD; Kingwell BA; Korjian S; Chi G; Lee JJ; Tricoci P; Kazmi SH; Fitzgerald C; Shaunik A; Berman G; Duffy D; Libby P
Curr Atheroscler Rep; 2022 Jul; 24(7):585-597. PubMed ID: 35524914
[TBL] [Abstract][Full Text] [Related]
10. Pharmacometric analyses to characterize the effect of CSL112 on apolipoprotein A-I and cholesterol efflux capacity in acute myocardial infarction patients.
Zheng B; Duffy D; Tricoci P; Kastrissios H; Pfister M; Wright SD; Gille A; Tortorici MA
Br J Clin Pharmacol; 2021 Jun; 87(6):2558-2571. PubMed ID: 33217027
[TBL] [Abstract][Full Text] [Related]
11. A multiple ascending dose study of CSL112, an infused formulation of ApoA-I.
Easton R; Gille A; D'Andrea D; Davis R; Wright SD; Shear C
J Clin Pharmacol; 2014 Mar; 54(3):301-10. PubMed ID: 24122814
[TBL] [Abstract][Full Text] [Related]
12. Effect of CSL112 (apolipoprotein A-I [human]) on cholesterol efflux capacity in Japanese subjects: Findings from a phase I study and a cross-study comparison.
Zheng B; Goto S; Clementi R; Feaster J; Duffy D; Dalitz P; Airey J; Korjian S; Tortorici MA; Roberts J; Gibson CM
Clin Transl Sci; 2022 Oct; 15(10):2331-2341. PubMed ID: 35933730
[TBL] [Abstract][Full Text] [Related]
13. CSL112, a reconstituted, infusible, plasma-derived apolipoprotein A-I: safety and tolerability profiles and implications for management in patients with myocardial infarction.
Capodanno D; Mehran R; Gibson CM; Angiolillo DJ
Expert Opin Investig Drugs; 2018 Dec; 27(12):997-1005. PubMed ID: 30376729
[TBL] [Abstract][Full Text] [Related]
14. CSL112 Infusion Rapidly Increases APOA1 Exchange Rate via Specific Serum Amyloid-Poor HDL Subpopulations When Administered to Patients Post-Myocardial Infarction.
Didichenko SA; Velkoska E; Navdaev AV; Greene BH; Lorkowski SW; Duffy D; Mears SJ; Wright SD; Gibson CM; Smith JD; Kingwell BA
Arterioscler Thromb Vasc Biol; 2023 Jun; 43(6):855-869. PubMed ID: 36994730
[TBL] [Abstract][Full Text] [Related]
15. A single infusion of MDCO-216 (ApoA-1 Milano/POPC) increases ABCA1-mediated cholesterol efflux and pre-beta 1 HDL in healthy volunteers and patients with stable coronary artery disease.
Kallend DG; Reijers JA; Bellibas SE; Bobillier A; Kempen H; Burggraaf J; Moerland M; Wijngaard PL
Eur Heart J Cardiovasc Pharmacother; 2016 Jan; 2(1):23-9. PubMed ID: 27418968
[TBL] [Abstract][Full Text] [Related]
16. Effects of the cholesteryl ester transfer protein inhibitor, TA-8995, on cholesterol efflux capacity and high-density lipoprotein particle subclasses.
van Capelleveen JC; Kastelein JJ; Zwinderman AH; van Deventer SJ; Collins HL; Adelman SJ; Round P; Ford J; Rader DJ; Hovingh GK
J Clin Lipidol; 2016; 10(5):1137-1144.e3. PubMed ID: 27678430
[TBL] [Abstract][Full Text] [Related]
17. Enhanced HDL Functionality in Small HDL Species Produced Upon Remodeling of HDL by Reconstituted HDL, CSL112: Effects on Cholesterol Efflux, Anti-Inflammatory and Antioxidative Activity.
Didichenko SA; Navdaev AV; Cukier AM; Gille A; Schuetz P; Spycher MO; Thérond P; Chapman MJ; Kontush A; Wright SD
Circ Res; 2016 Sep; 119(6):751-63. PubMed ID: 27436846
[TBL] [Abstract][Full Text] [Related]
18. The CSL112-2001 trial: Safety and tolerability of multiple doses of CSL112 (apolipoprotein A-I [human]), an intravenous formulation of plasma-derived apolipoprotein A-I, among subjects with moderate renal impairment after acute myocardial infarction.
Gibson CM; Kerneis M; Yee MK; Daaboul Y; Korjian S; Mehr AP; Tricoci P; Alexander JH; Kastelein JJP; Mehran R; Bode C; Lewis BS; Mehta R; Duffy D; Feaster J; Halabi M; Angiolillo DJ; Duerschmied D; Ophuis TO; Merkely B
Am Heart J; 2019 Feb; 208():81-90. PubMed ID: 30580130
[TBL] [Abstract][Full Text] [Related]
19. Cholesterol Efflux Capacity and Pre-Beta-1 HDL Concentrations Are Increased in Dyslipidemic Patients Treated With Evacetrapib.
Nicholls SJ; Ruotolo G; Brewer HB; Kane JP; Wang MD; Krueger KA; Adelman SJ; Nissen SE; Rader DJ
J Am Coll Cardiol; 2015 Nov; 66(20):2201-2210. PubMed ID: 26564598
[TBL] [Abstract][Full Text] [Related]
20. ApoA-IMilano phospholipid complex (ETC-216) infusion in human volunteers. Insights into the phenotypic characteristics of ApoA-IMilano carriers.
Bisgaier CL; Ackermann R; Rea T; Rodrigueza WV; Hartman D
Pharmacol Res; 2016 Sep; 111():86-99. PubMed ID: 27155060
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
